In this video, we explain Avenna’s core technology, GlyHealth. We explain the current four variants in our development pipeline including, GlyHealth-Index, IBD, SCI, and COVID-19, and expand on GlyHealth-Index and IBD. This video also compares conventional vs glycomic biomarkers for early detection and treatment personalisation of inflammatory disease.
CEO Nina Skorytechno talks about her journey towards founding Avenna and the challenges faced along the way. She also talks about being a female leadership in the BioTech field. Nina explains how Avenna technology can enhance the way current medicine is performed for inflammatory diseases and future prospects. This video expands on how our GlyHealth …
In our presentation at this renowned tech conference, our CEO discusses the burden of chronic inflammatory diseases (CIDs) and limitations in CIDs diagnostic procedures. . Additionally, this presentation explains how Avenna medical technology aims to reliably detect and predict future CIDs using molecular signals from blood samples.
In this video, we explain how Avenna’s innovative personalised precision medicine technology, GlyHealth can help to overcome current limitations faced in the healthcare sector. We also talk about the varieties of our solutions available to different members of the healthcare ecosystem, including Biopharmaceutical companies.